Triplet debuts with $59M, therapies for repeat expansion disorders

Triplet aims to treat repeat expansion disorders by targeting the DNA damage response pathway

When new research emerged last year pegging the DNA damage response pathway as a main driver of repeat expansion disorders, rather than the genetic mutations themselves, Atlas Venture co-founded and seeded Triplet with $10 million to design therapies based on the research. The company debuted Tuesday with a $49 million series A led by MPM Capital and Pfizer Ventures.

Atlas, Invus,

Read the full 603 word article

User Sign In